Search
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]
Axatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigational[A264309] Approved treatment options in steroid-refractory cGHVD are limited, and include [ruxolitinib], [ibrutinib], and [belumosudil]. … [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases.
Categories: Amino Acids, Peptides, and ProteinsBirabresib
go.drugbank.com/drugs/DB15189InvestigationalBirabresib is under investigation in clinical trial NCT02698176 (A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)).
Aminohippuric acid
go.drugbank.com/drugs/DB00345ApprovedInvestigationalWithdrawnIts sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]
Categories: Indicators and Reagents, Benzamides and benzamide derivativesAnacaulase
go.drugbank.com/drugs/DB17449ApprovedInvestigationalAnacaulase (anacaulase-bcdb) is a mixture of proteolytic enzymes extracted from the stems of pineapple plants (_Ananas comosus_ [L.] Merr.). … and the N-linked glycan of stem bromelain and small molecule metabolites.
Categories: Enzymes and CoenzymesAurothioglucose
go.drugbank.com/drugs/DB09121ApprovedWithdrawnThe use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action. … Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis [A32326].
Categories: Antiinflammatory and Antirheumatic ProductsProducts: Solganal Inj 50mg/mlHuman interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigationalHuman interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. … [A191784] Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.
Categories: Amino Acids, Peptides, and Proteins, Intercellular Signaling Peptides and ProteinsFerric oxide
go.drugbank.com/drugs/DB11576ApprovedInvestigationalIt is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.
Mixtures: Aveeno Calamine and Pramoxine Hydrochloride Anti ItchEteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigational[A244930] It is caused by loss-of-function mutations in the DMD gene coding for dystrophin, an essential protein involved in maintaining the structural integrity and function of muscle fibres. … [L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications.
Categories: Nucleic Acids, Nucleotides, and NucleosidesCM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 … (pancreatitis and SIRS), and NCT04661540 (critical COVID-19 pneumonia).